Erika Marzola

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3079020/publications.pdf

Version: 2024-02-01

30	678	566801 15	552369 26
papers	citations	h-index	g-index

30	30	30	680
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Synthesis of 2,6-Dimethyltyrosine-Like Amino Acids through Pinacolinamide-Enabled Câ€“H Dimethylation of 4-Dibenzylamino Phenylalanine. Journal of Organic Chemistry, 2022, 87, 2580-2589.	1.7	1
2	Pharmacology of Kappa Opioid Receptors: Novel Assays and Ligands. Frontiers in Pharmacology, 2022, 13, 873082.	1.6	3
3	Structureâ€“Activity Relationship Studies on Oxazolo[3,4-a]pyrazine Derivatives Leading to the Discovery of a Novel Neuropeptide S Receptor Antagonist with Potent In Vivo Activity. Journal of Medicinal Chemistry, 2021, 64, 4089-4108.	2.9	5
4	Use of a Novel Peptide Welding Technology Platform for the Development of B- and T-Cell Epitope-Based Vaccines. Vaccines, 2021, 9, 526.	2.1	1
5	Novel Mixed NOP/Opioid Receptor Peptide Agonists. Journal of Medicinal Chemistry, 2021, 64, 6656-6669.	2.9	7
6	Biased Agonism at Nociceptin/Orphanin FQ Receptors: A Structure Activity Study on N/OFQ(1â€“13)-NH₂. Journal of Medicinal Chemistry, 2020, 63, 10782-10795.	2.9	6
7	Tetrabranched Hetero-Conjugated Peptides as Bifunctional Agonists of the NOP and Mu Opioid Receptors. Bioconjugate Chemistry, 2019, 30, 2444-2451.	1.8	4
8	Pharmacological profile of the neuropeptide S receptor: Dynamic mass redistribution studies. Pharmacology Research and Perspectives, 2018, 6, e00445.	1.1	6
9	Structure- and conformation-activity studies of nociceptin/orphanin FQ receptor dimeric ligands. Scientific Reports, 2017, 7, 45817.	1.6	6
10	Structure activity studies of nociceptin/orphanin FQ(1â€“13)-NH2 derivatives modified in position 5. Bioorganic and Medicinal Chemistry, 2015, 23, 1515-1520.	1.4	6
11	A novel and facile synthesis of tetra branched derivatives of nociceptin/orphanin FQ. Bioorganic and Medicinal Chemistry, 2014, 22, 3703-3712.	1.4	32
12	Pharmacological characterization of tachykinin tetrabranched derivatives. British Journal of Pharmacology, 2014, 171, 4125-4137.	2.7	15
13	Thermodynamic and spectroscopic investigation on the role of Met residues in CuII binding to the non-octarepeat site of the human prion protein. Metallomics, 2012, 4, 794.	1.0	22
14	Role of 2â€²,6â€²-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds. Bioorganic and Medicinal Chemistry, 2010, 18, 6024-6030.	1.4	13
15	In Vitro and in Vivo Pharmacological Characterization of the Neuropeptide S Receptor Antagonist [d-Cys(tBu)5]Neuropeptide S. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 549-555.	1.3	55
16	Synthesis and Biological Activity of Human Neuropeptide S Analogues Modified in Position 5: Identification of Potent and Pure Neuropeptide S Receptor Antagonists. Journal of Medicinal Chemistry, 2009, 52, 524-529.	2.9	53
17	Further Studies at Neuropeptide S Position 5: Discovery of Novel Neuropeptide S Receptor Antagonists. Journal of Medicinal Chemistry, 2009, 52, 4068-4071.	2.9	24
18	Structureâ€“activity relationship study on Tyr9 of urotensin-II(4â€“11): Identification of a partial agonist of the UT receptor. Peptides, 2009, 30, 1130-1136.	1.2	9

#	Article	IF	Citations
19	Synthesis and antimicrobial activity of dermaseptin S1 analogues. Bioorganic and Medicinal Chemistry, 2008, 16, 8205-8209.	1.4	44
20	Structureâ€“activity study at positions 3 and 4 of human neuropeptide S. Bioorganic and Medicinal Chemistry, 2008, 16, 8841-8845.	1.4	15
21	Structureâ€“activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11). Peptides, 2008, 29, 674-679.	1.2	2
22	Synthesis and Biological Activity of Human Neuropeptide S Analogues Modified in Position 2. Journal of Medicinal Chemistry, 2008, 51, 655-658.	2.9	25
23	Conformationâ^'Activity Relationship of Neuropeptide S and Some Structural Mutants:Â Helicity Affects Their Interaction with the Receptor. Journal of Medicinal Chemistry, 2007, 50, 4501-4508.	2.9	21
24	Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with CÎ±,Î±-dialkylated amino acids. Bioorganic and Medicinal Chemistry, 2007, 15, 4434-4443.	1.4	51
25	In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5 ,D Trp7 ,Dab8]urotensin II(4-11) (UFP-803). British Journal of Pharmacology, 2006, 147, 92-100.	2.7	30
26	Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 373, 148-157.	1.4	21
27	Structure-Activity Studies on Neuropeptide S. Journal of Biological Chemistry, 2006, 281, 20809-20816.	1.6	89
28	Structure-activity relationship study on human urotensin II. Journal of Peptide Science, 2005, 11, 85-90.	0.8	34
29	N- and C-Terminal Modifications of Nociceptin/Orphanin FQ Generate Highly Potent NOP Receptor Ligands. Journal of Medicinal Chemistry, 2005, 48, 1421-1427.	2.9	25
30	Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. European Journal of Pharmacology, 2004, 498, 83-86.	1.7	53